KITE PHARMA INC's ticker is KITE and the CUSIP is 49803L109. A total of 252 filers reported holding KITE PHARMA INC in Q3 2017. The put-call ratio across all filers is 1.40 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $433,348,000 | +73.4% | 2,410,034 | 0.0% | 77.71% | +17.0% |
| Q2 2017 | $249,848,000 | +35.0% | 2,410,034 | +2.2% | 66.42% | +13.3% |
| Q1 2017 | $185,086,000 | +75.0% | 2,358,084 | 0.0% | 58.62% | +20.5% |
| Q4 2016 | $105,736,000 | -19.7% | 2,358,084 | 0.0% | 48.63% | +22.5% |
| Q3 2016 | $131,723,000 | +11.7% | 2,358,084 | 0.0% | 39.70% | -10.7% |
| Q2 2016 | $117,904,000 | +8.9% | 2,358,084 | 0.0% | 44.44% | +18.0% |
| Q1 2016 | $108,260,000 | -25.5% | 2,358,084 | 0.0% | 37.66% | -8.2% |
| Q4 2015 | $145,305,000 | +10.7% | 2,358,084 | 0.0% | 41.00% | -16.4% |
| Q3 2015 | $131,298,000 | -8.7% | 2,358,084 | 0.0% | 49.02% | -0.5% |
| Q2 2015 | $143,772,000 | +5.7% | 2,358,084 | 0.0% | 49.28% | -6.5% |
| Q1 2015 | $136,014,000 | +0.0% | 2,358,084 | 0.0% | 52.71% | -5.8% |
| Q4 2014 | $135,991,000 | – | 2,358,084 | – | 55.96% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wildcat Capital Management, LLC | 2,410,034 | $433,348,000 | 77.71% |
| COWEN INC. | 4,200,600 | $755,310,000 | 26.72% |
| Tyrus Capital S.A.M. | 1,314,812 | $236,416,000 | 18.49% |
| OMNI PARTNERS LLP | 661,711 | $118,982,000 | 15.19% |
| FNY Partners Fund LP | 379,510 | $68,239,000 | 11.61% |
| EQUITEC PROPRIETARY MARKETS, LLC | 240,100 | $43,172,000 | 10.15% |
| EQUITEC PROPRIETARY MARKETS, LLC | 227,500 | $40,907,000 | 9.62% |
| GARDNER LEWIS ASSET MANAGEMENT L P | 773,817 | $139,140,000 | 8.89% |
| Quad Capital Management Advisors LLC | 192,537 | $34,620,000 | 7.10% |
| Avoro Capital Advisors LLC | 496,983 | $89,363,000 | 6.93% |